| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8438397 | EBioMedicine | 2017 | 6 Pages |
Abstract
A high NLR, whether measured prior to or during treatment with IPI, is associated with worse OS, PFS, and clinical response in patients with advanced melanoma. An increasing NLR from baseline during treatment was correlated with worse OS and PFS in IPI-treated patients. In comparison, as NLR was not associated with outcomes in BRAFi patients, NLR may have a uniquely predictive value in patients treated with immunotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Michael R. Cassidy, Rachel E. Wolchok, Junting Zheng, Katherine S. Panageas, Jedd D. Wolchok, Daniel Coit, Michael A. Postow, Charlotte Ariyan,